Trevi Therapeutics to Participate in Upcoming August Conferences

Rhea-AI Summary

Trevi Therapeutics (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing its investigational therapy Haduvio (oral nalbuphine ER) for chronic cough in IPF, non-IPF ILD, and refractory chronic cough, will participate in two August 2026 biotech conferences: Oppenheimer's Biotech in the Berkshires on August 4 in Massachusetts and Stifel's 2026 Biotech Summer Summit on August 10-12 in Newport, Rhode Island, including an in-person fireside chat on August 10, 2:00–2:20 p.m. ET.

News Market Reaction – TRVI

+1.71%

1 alert

+1.71% Session close to close

$2.47B Market Cap

0.1x Rel. Volume

In the Jul 28 session, TRVI gained 1.71%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

Trevi’s June–July event schedule was followed by a 6.3% 24-hour reaction (news_id 1071702). Against ...

Analysis

Trevi’s June–July event schedule was followed by a 6.3% 24-hour reaction (news_id 1071702). Against that record, this announcement remained a scheduling update; moderate short positioning was a risk factor, and peer headlines were absent.

Key Figures

Oppenheimer conference date: August 4, 2026 Stifel summit dates: August 10-12, 2026 Fireside chat time: 2:00 p.m. to 2:20 p.m. ET

3 metrics

Oppenheimer conference date August 4, 2026 Biotech in the Berkshires

Stifel summit dates August 10-12, 2026 2026 Biotech Summer Summit

Fireside chat time 2:00 p.m. to 2:20 p.m. ET August 10, 2026

Historical Context

5 past events · Latest: Jun 17 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 17	Conference schedule	Neutral	+6.3%	June–July conference and event schedule announcement preceded a positive 24-hour price reaction.
May 05	Q1 earnings report	Negative	-2.7%	Earnings report included Q1 loss, financing proceeds, and cash-runway update; reaction was negative.
Apr 30	ATS presentation announcement	Neutral	+0.8%	ATS presentation and poster announcement preceded a positive 24-hour price reaction.
Apr 28	Earnings date notice	Neutral	-0.1%	Q1 earnings reporting-date notice preceded a slightly negative 24-hour price reaction.
Apr 23	Investor event schedule	Neutral	+1.6%	May investor-event participation announcement preceded a positive 24-hour price reaction.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Event-announcement history showed positive 24-hour reactions for three selected schedule or presentation notices, while the selected earnings report had a negative reaction.

Key Terms

idiopathic pulmonary fibrosis, interstitial lung disease, refractory chronic cough

3 terms

idiopathic pulmonary fibrosis medical

"chronic cough in patients with idiopathic pulmonary fibrosis (IPF)"

Idiopathic pulmonary fibrosis is a chronic lung disease in which the air‑carrying tissue becomes progressively thickened and scarred for no identifiable reason, making the lungs stiff and less able to move oxygen—similar to a sponge that hardens and loses its pores. It matters to investors because it is life‑limiting with limited effective treatments, so clinical trial outcomes, regulatory approvals, pricing and reimbursement decisions can strongly affect the commercial value of therapies and the financial prospects of companies developing treatments.

interstitial lung disease medical

"non-IPF interstitial lung disease (non-IPF ILD)"

A group of lung conditions that cause inflammation and scarring of the thin tissue between the air sacs, which makes it harder for oxygen to pass into the blood; imagine the lungs’ fine filters becoming stiff and less effective. Investors care because reports of interstitial lung disease can affect a drug’s safety profile, trigger regulatory warnings or label changes, and shift demand for treatments or create liability risks that influence a company’s valuation.

refractory chronic cough medical

"and refractory chronic cough (RCC), today announced"

A refractory chronic cough is a long-lasting cough that persists despite standard medical evaluation and treatment, typically lasting eight weeks or more and not improving with usual therapies. Investors should care because it represents a clear unmet medical need that can drive demand for new drugs, devices, or diagnostics—similar to a stubborn problem customers keep returning to a store for until a better solution appears—affecting market potential and regulatory attention.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW HAVEN, Conn., July 28, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will participate in the following conferences in August.

Oppenheimer's Biotech in the Berkshires
August 4, 2026, Berkshires, Massachusetts
Trevi Representative: Jennifer Good, President and CEO

Stifel's 2026 Biotech Summer Summit
August 10-12, 2026, Newport, Rhode Island
Fireside Chat (in-person): August 10, 2:00 p.m. to 2:20 p.m. ET
Trevi Representatives: Jennifer Good, President and CEO, and David Hastings, CFO

About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). In clinical trials, Haduvio showed a statistically-significant reduction in cough frequency, consistent across baseline cough frequencies and showed improvements in patient-reported outcomes, in both patients with IPF-related chronic cough and in patients with RCC. Haduvio is believed to act on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), targeting opioid receptors that play a key role in controlling chronic cough. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency.

Chronic cough in patients with IPF and non-IPF ILD is a condition with high unmet need and no FDA-approved therapies. There are ~140,000 U.S. patients with IPF, and two-thirds of these patients are faced with uncontrolled chronic cough. Additionally, there are ~228,000 U.S. patients with non-IPF ILD, with 50-60% having uncontrolled chronic cough. The impact of chronic cough is significant, with patients coughing up to 1,500 times per day. This consistent cough, and any associated damage, may lead to a higher risk of morbidity and mortality, including worsening disease, a higher risk of progression, increased respiratory hospitalizations, and a decline in patients' quality of life.

RCC is a condition with high unmet need and no FDA-approved therapies. RCC is defined as a persistent cough lasting >8 weeks despite treatment for an underlying condition (i.e., asthma, gastroesophageal reflux disease, non-asthmatic eosinophilic bronchitis, upper airway cough syndrome, or post-nasal drip) and includes unexplained chronic cough. There are ~2-3 million U.S. patients with RCC, and it is believed to be associated with cough reflex hypersensitivity involving both the central and peripheral nervous systems. RCC is highly debilitating and may impact patients physically, psychologically, and socially.

Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority.

For more information, visit www.TreviTherapeutics.com and follow Trevi on X (formerly Twitter) and LinkedIn.

Investor Contact 
Jonathan Carlson
Trevi Therapeutics, Inc.
(203) 654 3286
IR@trevitx.com

Media Contact
Rosalia Scampoli
914-815-1465
rscampoli@marketcompr.com

FAQ

What conferences will Trevi Therapeutics (TRVI) attend in August 2026?

Trevi Therapeutics will attend Oppenheimer's Biotech in the Berkshires on August 4, 2026, and Stifel's 2026 Biotech Summer Summit from August 10-12, 2026. According to Trevi, both conferences feature participation by senior management.

When is Trevi Therapeutics' fireside chat at Stifel's 2026 Biotech Summer Summit?

Trevi Therapeutics' in-person fireside chat is scheduled for August 10, 2026, from 2:00 p.m. to 2:20 p.m. ET. According to Trevi, this session is part of Stifel's 2026 Biotech Summer Summit in Newport, Rhode Island.

Who will represent Trevi Therapeutics (TRVI) at Oppenheimer's Biotech in the Berkshires 2026?

Trevi Therapeutics will be represented by Jennifer Good, its President and CEO, at Oppenheimer's Biotech in the Berkshires on August 4, 2026. According to Trevi, the event will take place in the Berkshires, Massachusetts.

Which Trevi Therapeutics executives will attend Stifel's 2026 Biotech Summer Summit?

Trevi Therapeutics will be represented by Jennifer Good, President and CEO, and David Hastings, CFO, at Stifel's 2026 Biotech Summer Summit. According to Trevi, they will participate in an in-person fireside chat on August 10, 2026.

What is Trevi Therapeutics' investigational therapy Haduvio being developed for?

Haduvio, an oral extended-release nalbuphine, is being developed for chronic cough in idiopathic pulmonary fibrosis, non-IPF interstitial lung disease, and refractory chronic cough. According to Trevi, Haduvio remains an investigational therapy in clinical development.